Supriya Lifescience Posts Strong FY26 Growth, Eyes INR 1000 Cr Revenue

FY26 Revenue INR 828 crore; Q4 FY26 Revenue INR 277 crore.

Reader Takeaway: Robust revenue growth and USFDA clearance are positives; margin moderation and working capital are watch points.

What just happened

Supriya Lifescience Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a significant 18.96% year-on-year growth in revenue for FY26, reaching INR 828 crore. This growth was primarily driven by a favourable product mix and increasing global demand. Notably, the fourth quarter of FY26 (Q4 FY26) saw a substantial 50% year-on-year increase in revenue to INR 277 crore, signalling strong performance from new product scaling.

Why this matters

The strong top-line performance indicates Supriya Lifescience's ability to capture market demand and effectively scale its product offerings. The successful USFDA inspection, resulting in a 'Voluntary Action Indicated' classification for its Lote facility, bolsters its regulatory credibility and supports potential export growth in key regulated markets. The company has also provided a clear revenue guidance of approximately INR 1,000 crore for FY27, offering investors visibility into future growth prospects.

The backstory

Supriya Lifescience, a key player in Active Pharmaceutical Ingredients (APIs), has been focused on expanding its presence in regulated markets and pursuing backward integration. The company has been investing in capacity expansion and R&D to drive future growth. The recent financial year saw significant capital expenditure, with INR 152 crore invested primarily for the Ambernath facility and maintenance.

What changes now

With a successful USFDA inspection and clear growth targets, the company is poised for continued expansion. The upcoming Patalganga project's Phase 1 development, slated to begin in FY27, along with capacity additions at the Ambernath and F block facilities, are expected to fuel the company's journey towards the INR 1,000 crore revenue mark. Management's focus on R&D, doubling spending with new labs, aims to launch 3-4 new products annually.

Risks to watch

While the revenue growth is impressive, the EBITDA margin saw a slight moderation, decreasing from 37.5% in FY25 to 35.5% in FY26. This indicates a need to monitor cost efficiencies and product mix economics. Additionally, the company's net working capital days stood at 170 days, which requires continuous monitoring due to its impact on cash flow. The pending audit schedule for the Ambernath facility also presents a potential watch point, as regulatory approvals are critical for revenue ramp-up.

Peer comparison

[Grounded search for peer comparison not available or unreliable. Content will be based solely on filing.]

Context metrics (time-bound)

• Revenue: Grew 18.96% to INR 828 crore in FY26 from INR 696 crore in FY25.
• EBITDA: Increased 12.64% to INR 294 crore in FY26 from INR 261 crore in FY25.
• Q4 FY26 Revenue: Increased 50% year-on-year to INR 277 crore.
• Capex: INR 152 crore incurred in FY26.
• Working Capital: 170 days.

What to track next

Investors will be keen to observe the progress of the Patalganga project and the operationalization of the Ambernath facility. The timely completion and positive outcome of regulatory audits, particularly for the Ambernath site, will be crucial for sustained growth. Monitoring EBITDA margins and working capital efficiency will also be key performance indicators.